FATE reported updated data in June from its phase 1 study of FT819, a CD19-targeting cell therapy, in autoimmune disease. That data demonstrates the potential to administer FT819, and see benefit in ...
GameSpot may get a commission from retail offers. Warning: This article contains spoilers for Destiny 2's latest expansion, The Edge of Fate. We recommend you complete its story campaign before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback